Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Polyarticular-course JIA (PASCAL)
NCT01550003Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2012
- Primary completion
- Apr 2024
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 3 trial of certolizumab pegol in juvenile idiopathic arthritis (JIA), sponsored by UCB. Started Mar 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT01550003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01550003.